VR avatar therapy for psychosis: linking thinking, self-awareness, and social cognition

Evaluation of Cognitive, Metacognitive, Social Cognition and Trauma Related-Variables in Patients With Psychosis Receiving VR-Based Avatar Therapy

Not applicable Interventional Fundació Sant Joan de Déu · NCT07091344

This project will test whether cognitive, metacognitive, and social-cognition factors relate to how well VR-based avatar therapy helps people with schizophrenia who have persistent auditory hallucinations.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment30 (estimated)
Ages18 Years and up
SexAll
SponsorFundació Sant Joan de Déu Academic / other
Locations1 site (Barcelona, Catalonia)
Trial IDNCT07091344 on ClinicalTrials.gov

What this trial studies

Participants with schizophrenia and ongoing auditory hallucinations will receive seven individual VR-based avatar therapy sessions delivered over a 12-week intervention period. Researchers will measure neurocognition, metacognition, emotion recognition, attributional style, theory of mind, and social perception using validated tools at screening, baseline, during therapy, and at a post-therapy follow-up. Childhood trauma will also be measured to explore its role as a predisposing factor. The goal is to identify which cognitive and metacognitive profiles predict better or worse therapy outcomes to inform more personalized approaches.

Who should consider this trial

Good fit: Adults (18+) with a DSM-5 schizophrenia-spectrum diagnosis, persistent auditory hallucinations despite treatment, stable medication for at least four weeks, fluent in Spanish, and able to attend in-person VR sessions are ideal candidates.

Not a fit: People who cannot tolerate VR, have severe visual or neurological impairments, active substance abuse, intellectual disability, current suicidal risk, or who cannot identify a dominant voice for the avatar may not benefit from this intervention.

Why it matters

Potential benefit: If successful, the study could help tailor VR avatar therapy to individuals by identifying cognitive or metacognitive traits linked to better outcomes.

How similar studies have performed: Previous avatar-based VR interventions for auditory hallucinations have shown promising results, but combining them with detailed cognitive and metacognitive profiling is a relatively novel approach.

Eligibility criteria

Show full inclusion / exclusion criteria
\*\*Inclusion Criteria:\*\*

* Adults aged 18 years or older.
* Diagnosis of schizophrenia spectrum disorder according to DSM-5 criteria.
* Experience of persistent auditory hallucinations for at least 3 months (PANSS hallucination score ≥ 3).
* Stable medication dosage for at least 4 weeks prior to recruitment.
* Fluent in the spoken language of the study site (Spanish).
* Able to provide informed consent.
* Regular psychiatric follow-up care.

\*\*Exclusion Criteria:\*\*

* Inability to identify a dominant voice for Avatar Therapy intervention.
* Intellectual disability based on medical history.
* Active substance abuse.
* Central nervous system injury or neurological disorders affecting cognitive performance.
* Severe visual impairment that precludes the use of VR technology.
* Aversion to virtual reality or prior experience of simulator sickness.
* Current suicidal ideation or risk.
* Lack of cooperation or inability to comply with study procedures.

Where this trial is running

Barcelona, Catalonia

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Schizophrenia DisordersTreatment Resistant HallucinationsVR-based Avatar Therapycognitionmetacognitionsocial cognitionpsychosisschizophrenia spectrum disorders
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.